Evidence supporting the use of: Ibutamoren
For the body system: Pituitary
Synopsis
Source of validity: Scientific
Rating (out of 5): 4
Ibutamoren (also known as MK-677) is a non-peptide agonist of the ghrelin receptor and a potent stimulator of growth hormone (GH) secretion. Its use to support the pituitary body system is based on scientific evidence from multiple clinical studies showing that it increases circulating levels of growth hormone and insulin-like growth factor 1 (IGF-1) in humans. Unlike exogenous growth hormone administration, Ibutamoren stimulates the pituitary gland to produce more GH endogenously, thereby supporting normal pituitary function. Clinical studies in both elderly and young adults have demonstrated that daily administration of Ibutamoren increases GH and IGF-1 levels without significantly affecting cortisol levels. Additionally, studies have examined its effects in patients with GH deficiency, and in these populations, Ibutamoren has shown promise in restoring physiological GH secretion patterns. However, while the evidence supporting its ability to stimulate pituitary GH release is robust, long-term safety and efficacy data are still limited, and it is not approved by regulatory agencies for this use outside of clinical trials. The available studies do validate its mechanism of action via the pituitary gland, making its use scientifically justified for supporting this body system, though its use remains investigational.
Other body systems supported by Ibutamoren
BrainGlandular System
Hypothalamus
Muscles
Pituitary
Pituitary (anterior)
Skeletal System (Bones)